MOREPENLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Morepen Laboratories Says Court Grants Stay On 1.18 Billion Rupees Tax Demand Against Co
Jan 8 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES - COURT GRANTS STAY ON 1.18 BILLION RUPEES TAX DEMAND AGAINST CO
Source text: ID:nNSE7gzGQR
Further company coverage: MORL.NS
(([email protected];))
Jan 8 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES - COURT GRANTS STAY ON 1.18 BILLION RUPEES TAX DEMAND AGAINST CO
Source text: ID:nNSE7gzGQR
Further company coverage: MORL.NS
(([email protected];))
India's Morepen Laboratories rises after unit to form joint venture
Morepen Laboratories Says Morepen Medipath Forms Joint Venture With Bimedical
India's Morepen Labs jumps on new drug launches
** Shares of Morepen Laboratories MORL.NS jump as much as 17% to 64 rupees, their highest level since February 6
** Pharma co announces launch of four new products - Ticapen, UdoFix, LycoMore and Acifix used for cardiovascular health, liver health, nutrition and heartburn, respectively
** MORL targets to grow formulation business to 10 billion rupees ($117.2 million) in five years from 3.25 billion rupees currently
** More than 30 mln shares traded, trading vols at 5x their 30-day avg
** Stock is down 20% so far in 2025
($1 = 85.3280 Indian rupees)
(Reporitng by Nishit Navin)
(([email protected];))
** Shares of Morepen Laboratories MORL.NS jump as much as 17% to 64 rupees, their highest level since February 6
** Pharma co announces launch of four new products - Ticapen, UdoFix, LycoMore and Acifix used for cardiovascular health, liver health, nutrition and heartburn, respectively
** MORL targets to grow formulation business to 10 billion rupees ($117.2 million) in five years from 3.25 billion rupees currently
** More than 30 mln shares traded, trading vols at 5x their 30-day avg
** Stock is down 20% so far in 2025
($1 = 85.3280 Indian rupees)
(Reporitng by Nishit Navin)
(([email protected];))
Morepen Laboratories - Executes Business Transfer Agreement With Unit Morepen Medtech
Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES - EXECUTES BUSINESS TRANSFER AGREEMENT WITH UNIT MOREPEN MEDTECH
Source text: ID:nBSE2j98H
Further company coverage: MORL.NS
Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES - EXECUTES BUSINESS TRANSFER AGREEMENT WITH UNIT MOREPEN MEDTECH
Source text: ID:nBSE2j98H
Further company coverage: MORL.NS
Morepen Laboratories Ltd - Launches Empamore For Diabetes, Heart Failure, And Kidney Disease
Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - LAUNCHES EMPAMORE FOR DIABETES, HEART FAILURE, AND KIDNEY DISEASE
Source text: ID:nBSE6jPcgn
Further company coverage: MORL.NS
Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - LAUNCHES EMPAMORE FOR DIABETES, HEART FAILURE, AND KIDNEY DISEASE
Source text: ID:nBSE6jPcgn
Further company coverage: MORL.NS
Morepen Laboratories Dec-Qtr Net Profit 226.8 Million Rupees
Feb 6 (Reuters) - Morepen Laboratories Ltd MORL.NS:
DEC-QUARTER NET PROFIT 226.8 MILLION RUPEES
DEC-QUARTER INCOME FROM OPERATIONS 4.03 BILLION RUPEES
Source text: ID:nBSEbls5hn
Further company coverage: MORL.NS
(([email protected];))
Feb 6 (Reuters) - Morepen Laboratories Ltd MORL.NS:
DEC-QUARTER NET PROFIT 226.8 MILLION RUPEES
DEC-QUARTER INCOME FROM OPERATIONS 4.03 BILLION RUPEES
Source text: ID:nBSEbls5hn
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories Approves Hiving Off Medical Devices Business
Jan 15 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - APPROVES HIVING OFF MEDICAL DEVICES BUSINESS
MOREPEN LABORATORIES LTD - SLUMP SALE OF MEDICAL DEVICES EXPECTED TO COMPLETE BY SEPTEMBER 30, 2025
Source text: ID:nNSE3S5V9H
Further company coverage: MORL.NS
(([email protected];;))
Jan 15 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - APPROVES HIVING OFF MEDICAL DEVICES BUSINESS
MOREPEN LABORATORIES LTD - SLUMP SALE OF MEDICAL DEVICES EXPECTED TO COMPLETE BY SEPTEMBER 30, 2025
Source text: ID:nNSE3S5V9H
Further company coverage: MORL.NS
(([email protected];;))
Morepen Laboratories Approves Hiving Off Medical Devices Business
Jan 14 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - APPROVES HIVING OFF MEDICAL DEVICES BUSINESS
MOREPEN LABORATORIES - HIVING OFF MEDICAL DEVICES BUSINESS TO MOREPEN MEDTECH
Source text: ID:nNSE4M6Km8
Further company coverage: MORL.NS
(([email protected];))
Jan 14 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - APPROVES HIVING OFF MEDICAL DEVICES BUSINESS
MOREPEN LABORATORIES - HIVING OFF MEDICAL DEVICES BUSINESS TO MOREPEN MEDTECH
Source text: ID:nNSE4M6Km8
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories To Incorporate New Unit
Dec 27 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - TO INCORPORATE NEW SUBSIDIARY
Source text: ID:nNSEbjW8ys
Further company coverage: MORL.NS
(([email protected];))
Dec 27 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD - TO INCORPORATE NEW SUBSIDIARY
Source text: ID:nNSEbjW8ys
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories Says Dr. Morepen Targets Revenue Of 300 Mln Rupees In First Year From Lightlife
Dec 11 (Reuters) - Morepen Laboratories Ltd MORL.NS:
DR. MOREPEN TARGETING REVENUE OF 300 MILLION RUPEES IN FIRST YEAR FROM LIGHTLIFE
DR. MOREPEN HAS GOAL OF 1 BILLION RUPEES REVENUE OVER NEXT THREE YEARS FROM LIGHTLIFE
Further company coverage: MORL.NS
(([email protected];))
Dec 11 (Reuters) - Morepen Laboratories Ltd MORL.NS:
DR. MOREPEN TARGETING REVENUE OF 300 MILLION RUPEES IN FIRST YEAR FROM LIGHTLIFE
DR. MOREPEN HAS GOAL OF 1 BILLION RUPEES REVENUE OVER NEXT THREE YEARS FROM LIGHTLIFE
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories Says Sept-Quarter Consol Net Profit At 348.5 Million Rupees
Nov 11 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES SEPT-QUARTER CONSOL NET PROFIT 348.5 MILLION RUPEES
MOREPEN LABORATORIES SEPT-QUARTER CONSOL TOTAL INCOME 4.43 BILLION RUPEES
Source text: [ID:]
Further company coverage: MORL.NS
(([email protected];))
Nov 11 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES SEPT-QUARTER CONSOL NET PROFIT 348.5 MILLION RUPEES
MOREPEN LABORATORIES SEPT-QUARTER CONSOL TOTAL INCOME 4.43 BILLION RUPEES
Source text: [ID:]
Further company coverage: MORL.NS
(([email protected];))
India's Morepen Labs soars to around 13-year high
** Shares of Morepen Laboratories Ltd MORL.NS up 13% at 92.89 rupees, their highest since December 2001
** Around 1.9 mln shares of active pharmaceutical ingredients maker traded in 3 separate block deals, all at a premium to previous closing price of 82.22 rupees
** Overall, 64.8 mln shares traded vs 30-day avg volume of 25.8 mln shares
** Stock up ~93% so far this year
(Reporting by Nandan Mandayam in Bengaluru)
(([email protected]; Mobile: +91 9591011727;))
** Shares of Morepen Laboratories Ltd MORL.NS up 13% at 92.89 rupees, their highest since December 2001
** Around 1.9 mln shares of active pharmaceutical ingredients maker traded in 3 separate block deals, all at a premium to previous closing price of 82.22 rupees
** Overall, 64.8 mln shares traded vs 30-day avg volume of 25.8 mln shares
** Stock up ~93% so far this year
(Reporting by Nandan Mandayam in Bengaluru)
(([email protected]; Mobile: +91 9591011727;))
Morepen Laboratories June-Quarter Consol Net Profit At 361.7 Million Rupees
Aug 12 (Reuters) - Morepen Laboratories Ltd MORL.NS:
JUNE-QUARTER CONSOL NET PROFIT 361.7 MILLION RUPEES
JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 4.55 BILLION RUPEES
Further company coverage: MORL.NS
(([email protected];))
Aug 12 (Reuters) - Morepen Laboratories Ltd MORL.NS:
JUNE-QUARTER CONSOL NET PROFIT 361.7 MILLION RUPEES
JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 4.55 BILLION RUPEES
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories Raises 2 Bln Rupees Via QIP
Aug 6 (Reuters) - Morepen Laboratories Ltd MORL.NS:
RAISES 2 BILLION RUPEES VIA QIP
Source text for Eikon: ID:nBSE4LjHM9
Further company coverage: MORL.NS
(([email protected];;))
Aug 6 (Reuters) - Morepen Laboratories Ltd MORL.NS:
RAISES 2 BILLION RUPEES VIA QIP
Source text for Eikon: ID:nBSE4LjHM9
Further company coverage: MORL.NS
(([email protected];;))
Morepen Laboratories Authorised The Opening Of QIP Issue On Aug 1
Aug 1 (Reuters) - Morepen Laboratories Ltd MORL.NS:
AUTHORISED THE OPENING OF QIP ISSUE ON AUG 1
APPROVED FLOOR PRICE FOR QIP AT 57.23 RUPEES PER SHARE
Source text for Eikon: ID:nNSE9q710P
Further company coverage: MORL.NS
(([email protected];))
Aug 1 (Reuters) - Morepen Laboratories Ltd MORL.NS:
AUTHORISED THE OPENING OF QIP ISSUE ON AUG 1
APPROVED FLOOR PRICE FOR QIP AT 57.23 RUPEES PER SHARE
Source text for Eikon: ID:nNSE9q710P
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories March-Quarter Consol Net Profit Rises
May 21 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET PROFIT 287.4 MILLION RUPEES VERSUS PROFIT 82.4 MILLION RUPEES
MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET INCOME FROM OPERATIONS 4.23 BILLION RUPEES VERSUS 3.64 BILLION RUPEES
Source text for Eikon: ID:nBSE7yr18k
Further company coverage: MORL.NS
(([email protected];))
May 21 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET PROFIT 287.4 MILLION RUPEES VERSUS PROFIT 82.4 MILLION RUPEES
MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET INCOME FROM OPERATIONS 4.23 BILLION RUPEES VERSUS 3.64 BILLION RUPEES
Source text for Eikon: ID:nBSE7yr18k
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories Approved Raising Of Funds Worth Upto 3.5 Bln Rupees
Feb 22 (Reuters) - Morepen Laboratories Ltd MORL.NS:
APPROVED RAISING OF FUNDS WORTH UPTO 3.5 BILLION RUPEES
Source text for Eikon: ID:nNSE4RkQzT
Further company coverage: MORL.NS
(([email protected];))
Feb 22 (Reuters) - Morepen Laboratories Ltd MORL.NS:
APPROVED RAISING OF FUNDS WORTH UPTO 3.5 BILLION RUPEES
Source text for Eikon: ID:nNSE4RkQzT
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories To Consider Fund Raising
Feb 19 (Reuters) - Morepen Laboratories Ltd MORL.NS:
TO CONSIDER FUND RAISING
Source text for Eikon: ID:nBSE9Gdhgt
Further company coverage: MORL.NS
(([email protected];))
Feb 19 (Reuters) - Morepen Laboratories Ltd MORL.NS:
TO CONSIDER FUND RAISING
Source text for Eikon: ID:nBSE9Gdhgt
Further company coverage: MORL.NS
(([email protected];))
Morepen Laboratories Ltd- Approved Transfer Of Formulation Distribution & Marketing Business To Morepen Rx
Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD- APPROVED TRANSFER OF FORMULATION DISTRIBUTION & MARKETING BUSINESS TO MOREPEN RX
MOREPEN LABORATORIES LTD- DEAL FOR 70.3 MILLION RUPEES
Source text for Eikon: ID:nNSE6Rk67N
Further company coverage: MORL.NS
Morepen Laboratories Ltd MORL.NS:
MOREPEN LABORATORIES LTD- APPROVED TRANSFER OF FORMULATION DISTRIBUTION & MARKETING BUSINESS TO MOREPEN RX
MOREPEN LABORATORIES LTD- DEAL FOR 70.3 MILLION RUPEES
Source text for Eikon: ID:nNSE6Rk67N
Further company coverage: MORL.NS
India's Morepen Laboratories surges as profit triples in June quarter
** Shares of Morepen Laboratories MORL.NS surge as much as 14.59% to a near seven-month high of 34.95 rupees
** The pharmaceutical firm's net profit almost triples year-on-year to 145.33 mln rupees in June quarter
** Revenue jumps ~33% to 4.01 bln rupees; EBITDA nearly doubles to 260.89 mln rupees
** Co reappoints Sushil Suri as the Chairman and Managing Director for a further three-year period, effective from Oct. 20, 2023
** Relative strength index rises above 70, suggesting the stock may be overbought
** Stock most active in nearly two months, with a trading volume of 21.71 mln shares as of 12:42 p.m. IST, nearly seven times the 30-day avg - Refinitiv data
** Including Monday's gains, MORL down 11.49% in 2023 so far, compared to 22.35% rise in pharma index .NIPHARM
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of Morepen Laboratories MORL.NS surge as much as 14.59% to a near seven-month high of 34.95 rupees
** The pharmaceutical firm's net profit almost triples year-on-year to 145.33 mln rupees in June quarter
** Revenue jumps ~33% to 4.01 bln rupees; EBITDA nearly doubles to 260.89 mln rupees
** Co reappoints Sushil Suri as the Chairman and Managing Director for a further three-year period, effective from Oct. 20, 2023
** Relative strength index rises above 70, suggesting the stock may be overbought
** Stock most active in nearly two months, with a trading volume of 21.71 mln shares as of 12:42 p.m. IST, nearly seven times the 30-day avg - Refinitiv data
** Including Monday's gains, MORL down 11.49% in 2023 so far, compared to 22.35% rise in pharma index .NIPHARM
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
Morepen Laboratories Says India Supreme Court Orders Stay On Contempt Proceedings Against Co, Directors Pending Before NCLT
May 30 (Reuters) - Morepen Laboratories Ltd MORL.NS:
INDIA SUPREME COURT ORDERED STAY ON CONTEMPT PROCEEDINGS AGAINST CO, DIRECTORS PENDING BEFORE NCLT
Source text for Eikon: ID:nBSE5BBnV2
Further company coverage: MORL.NS
(([email protected];))
May 30 (Reuters) - Morepen Laboratories Ltd MORL.NS:
INDIA SUPREME COURT ORDERED STAY ON CONTEMPT PROCEEDINGS AGAINST CO, DIRECTORS PENDING BEFORE NCLT
Source text for Eikon: ID:nBSE5BBnV2
Further company coverage: MORL.NS
(([email protected];))
India's Morepen Laboratories loses 3% on fall in Q4 earnings
** Shares of Morepen Laboratories Ltd MORL.NS fall as much as 3.14% to 26.20 rupees, a three-week low
** Pharma firm reports 33% fall in consolidated net profit in March quarter to 82.4 mln rupees from 123.2 mln rupees a year earlier nFWN37D1E6
** Consolidated income from operations falls 1% to 3.64 bln rupees from 3.68 bln rupees Y/Y
** Core profit slips 27% YoY to 155.59 mln rupees; core profit margins contract to 4.27% from 5.07%
** Trading volume is 1.52 mln shares as of 12:49 p.m. IST, half the 30-day avg - Refintiv data
($1 = 81.7800 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of Morepen Laboratories Ltd MORL.NS fall as much as 3.14% to 26.20 rupees, a three-week low
** Pharma firm reports 33% fall in consolidated net profit in March quarter to 82.4 mln rupees from 123.2 mln rupees a year earlier nFWN37D1E6
** Consolidated income from operations falls 1% to 3.64 bln rupees from 3.68 bln rupees Y/Y
** Core profit slips 27% YoY to 155.59 mln rupees; core profit margins contract to 4.27% from 5.07%
** Trading volume is 1.52 mln shares as of 12:49 p.m. IST, half the 30-day avg - Refintiv data
($1 = 81.7800 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
India's Morepen Laboratories March-Quarter Consol Net Profit Falls
May 16 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MARCH-QUARTER CONSOL NET PROFIT 82.4 MILLION RUPEES VERSUS 123.2 MILLION RUPEES
MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 3.64 BILLION RUPEES VERSUS 3.68 BILLION RUPEES
Further company coverage: MORL.NS
(([email protected];))
May 16 (Reuters) - Morepen Laboratories Ltd MORL.NS:
MARCH-QUARTER CONSOL NET PROFIT 82.4 MILLION RUPEES VERSUS 123.2 MILLION RUPEES
MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 3.64 BILLION RUPEES VERSUS 3.68 BILLION RUPEES
Further company coverage: MORL.NS
(([email protected];))
Upcoming Events:
Quarterly Results
Events:
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Morepen Laboratories do?
Morepen Laboratories is a pharmaceutical company manufacturing APis, Home Diagnostics, and OTC products. They specialize in anti-allergy drug Loratadine and are prominent in Blood Glucose Monitors and Blood Pressure Monitors domestically.
Who are the competitors of Morepen Laboratories?
Morepen Laboratories major competitors are IOL Chem & Pharma, Solara Active Pharma, NGL Fine-Chem, Hester Biosciences, Bajaj Healthcare, SMS Pharmaceuticals, Themis Medicare. Market Cap of Morepen Laboratories is ₹2,078 Crs. While the median market cap of its peers are ₹1,409 Crs.
Is Morepen Laboratories financially stable compared to its competitors?
Morepen Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Morepen Laboratories is 4.46 and is ranked 4 out of its 8 competitors.
Does Morepen Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Morepen Laboratories latest dividend payout ratio is 9.29% and 3yr average dividend payout ratio is 9.29%
How has Morepen Laboratories allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Morepen Laboratories balance sheet?
Balance sheet of Morepen Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Morepen Laboratories improving?
The profit is oscillating. The profit of Morepen Laboratories is ₹99.45 Crs for TTM, ₹118 Crs for Mar 2025 and ₹96.16 Crs for Mar 2024.
Is the debt of Morepen Laboratories increasing or decreasing?
Yes, The net debt of Morepen Laboratories is increasing. Latest net debt of Morepen Laboratories is ₹105 Crs as of Sep-25. This is greater than Mar-25 when it was -₹19.22 Crs.
Is Morepen Laboratories stock expensive?
Morepen Laboratories is not expensive. Latest PE of Morepen Laboratories is 20.4, while 3 year average PE is 28.66. Also latest EV/EBITDA of Morepen Laboratories is 15.89 while 3yr average is 18.5.
Has the share price of Morepen Laboratories grown faster than its competition?
Morepen Laboratories has given lower returns compared to its competitors. Morepen Laboratories has grown at ~11.2% over the last 7yrs while peers have grown at a median rate of 16.6%
Is the promoter bullish about Morepen Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Morepen Laboratories is 35.65% and last quarter promoter holding is 35.65%.
Are mutual funds buying/selling Morepen Laboratories?
There is Insufficient data to gauge this.